Brokerages Set Agenus Inc. (NASDAQ:AGEN) Target Price at $14.00

Agenus Inc. (NASDAQ:AGEN) has earned an average recommendation of “Hold” from the six analysts that are currently covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $14.00.

A number of research firms recently issued reports on AGEN. Robert W. Baird boosted their target price on shares of Agenus from $4.00 to $6.00 and gave the company a “neutral” rating in a report on Wednesday, June 4th. Wall Street Zen upgraded shares of Agenus from a “strong sell” rating to a “hold” rating in a report on Thursday, May 22nd. B. Riley restated a “buy” rating on shares of Agenus in a report on Monday, April 21st. Finally, HC Wainwright upgraded shares of Agenus from a “neutral” rating to a “buy” rating and set a $25.00 target price for the company in a report on Wednesday, June 4th.

Institutional Investors Weigh In On Agenus

Several institutional investors have recently bought and sold shares of AGEN. Apollon Wealth Management LLC purchased a new stake in Agenus during the fourth quarter worth approximately $55,000. Virtu Financial LLC purchased a new stake in Agenus during the fourth quarter worth approximately $51,000. Bank of Montreal Can purchased a new stake in Agenus during the fourth quarter worth approximately $69,000. Barclays PLC grew its stake in Agenus by 17.7% during the fourth quarter. Barclays PLC now owns 32,737 shares of the biotechnology company’s stock worth $90,000 after buying an additional 4,924 shares during the period. Finally, Gilead Sciences Inc. purchased a new stake in Agenus during the fourth quarter worth approximately $635,000. 61.46% of the stock is currently owned by hedge funds and other institutional investors.

Agenus Price Performance

Agenus stock opened at $4.70 on Monday. Agenus has a 12-month low of $1.38 and a 12-month high of $18.74. The stock has a market capitalization of $128.86 million, a P/E ratio of -0.42 and a beta of 1.43. The firm’s 50-day moving average is $3.32 and its two-hundred day moving average is $3.02.

Agenus (NASDAQ:AGEN) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.61) by $0.58. The firm had revenue of $24.07 million for the quarter, compared to analyst estimates of $26.38 million. As a group, analysts forecast that Agenus will post -12.55 EPS for the current year.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.